<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430261</url>
  </required_header>
  <id_info>
    <org_study_id>CRC 05160</org_study_id>
    <nct_id>NCT00430261</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma</brief_title>
  <official_title>Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer.
      The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a
      never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of
      adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To participate in this study, patients must have disease that can be measured on a CT scan.
      Brain metastases are OK if stable. Pregnant and/or nursing women may not participate. This
      drug has been approved by the FDA for the treatment of advanced renal cell cancer and a
      certain type of stomach/intestinal cancer. Its efficacy in lung cancer in currently unknown.
      Common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood
      counts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>January 2009</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Adenocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.</description>
    <other_name>SU011248</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bronchoalveolar carcinoma with disease measurable on CAT scan

          -  Any lung adenocarcinoma in a never-smoker (less than 100 cigarettes lifetime) with
             disease measurable on CAT scan

          -  Stage IIIB or IV

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Unstable brain metastases

          -  Pregnant/nursing women

          -  Uncontrolled thyroid disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard West, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.swedish.org/body.cfm?id=19&amp;oTopID=19</url>
    <description>Swedish Cancer Institute website</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>October 5, 2010</last_update_submitted>
  <last_update_submitted_qc>October 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Howard jack West, M.D.</name_title>
    <organization>Swedish Medical Center, Swedish Cancer Institute</organization>
  </responsible_party>
  <keyword>bronchoalveolar carcinoma</keyword>
  <keyword>BAC</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>lung cancer</keyword>
  <keyword>oral</keyword>
  <keyword>Stage IIIB and IV lung cancer</keyword>
  <keyword>Any bronchoalveolar carcinoma (BAC)</keyword>
  <keyword>Any adenocarcinoma in a never-smoker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma, Bronchiolo-Alveolar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

